312904-99-7

Basic information

• Product Name: 2-Pyridinecarbonitrile,3-fluoro-4-methyl-(9CI)
• Synonyms: 3-Fluoro-4-methylpyridine-2-carbonitrile;3-fluoro-4-Methyl-2-Pyridinecarbonitrile;2-Pyridinecarbonitrile,3-fluoro-4-methyl-(9CI)
• CAS NO: 312904-99-7
• Molecular Formula: C₇H₅FN₂
• Molecular Weight: 136.128
• Product Categories: PYRIDINE
• Mol File: 312904-99-7.mol

Chemical Properties

• Boiling Point: 242℃
• Flash Point: 100℃
• Appearance: /
• Density: 1.19
• CAS DataBase Reference: 2-Pyridinecarbonitrile,3-fluoro-4-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarbonitrile,3-fluoro-4-methyl-(9CI)(312904-99-7)
• EPA Substance Registry System: 2-Pyridinecarbonitrile,3-fluoro-4-methyl-(9CI)(312904-99-7)

Safety Data

• Hazardous Substances Data: 312904-99-7(Hazardous Substances Data)

Upstream product

• 33252-59-4 3-fluoro-4-methylpyridine-N-oxide 
• 7677-24-9 trimethylsilyl cyanide 
• 399-88-2 3-fluoro-4-methylpyridine 
• 557-21-1 zinc(II) cyanide 
• 884494-37-5 2-bromo-3-fluoro-4-methylpyridine 
• 557-21-1 dicyanozinc 
• 372-47-4 3-Fluoropyridine 

Downstream Products

• 1034709-16-4 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carbonitrile 
• 1155847-57-6 C₁₃H₉ClN₂O₂ 
• 1155846-65-3 3-chloro-5-{[4-methyl-2-oxo-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1,2-dihydropyridin-3-yl]oxy}benzonitrile 
• 1034709-24-4 3-(3-bromo-5-chlorophenoxy)-4-methylpyridine-2-carboxylic acid 
• 756807-57-5 2-aminomethyl-3-fluoro-4-methylpyridine 

Relevant articles and documents

Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase

Next generation NNRTIs are sought which possess both broad spectrum antiviral activity against key mutant strains and a high genetic barrier to the selection of new mutant viral strains. Pyridones were evaluated as an acyclic conformational constraint to

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Heteroaromatic compounds of Formula (I), are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B,

Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines

Recent efforts in the field of thrombin inhibitor research have focused on the identification of compounds with good oral bioavailability and pharmacokinetics. In this manuscript we describe a metabolism-based approach to the optimization of the 3-(2-phen

THROMBIN INHIBITORS

Compounds of the invention, useful as thrombin inhibitors and having therapeutic value in for example, preventing coronary artery disease, have the following structure: or a pharmaceutically acceptable salt thereof, whereinA is whereinY 1 and Y 2 are independentlyhydrogen,C 1-4 alkyl,C 1-4 alkoxy,F uH v C(CH 2) 0-1 O--, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1,C 3-7 cycloalkyl,thio C 1-4 alkyl,C 1-4 sulfinylalkyl,C 1-4 sulfonylalkyl, halogencyano, ortrifluoromethyl, andwherein b is 0 or 1.

Pyrazinone thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: A is ?wherein Y1and Y2are independently hydrogen, C1-4alkyl, C1-4alkoxy, FuHvC(CH2)0-1O—, wherein u and v are either 1 or 2, provided that when u is 1, v is 2, and when u is 2, v is 1, C3-7cycloalkyl, thio C1-4alkyl, C1-4sulfinylalkyl, C1-4sulfonylalkyl, halogen cyano, or trifluoromethyl, and wherein b is 0 or 1.